Our goal is to be a global leader of human vaccines and anti-viral drugs, that deliver a long-lasting therapeutic effect to treat some of the world’s most threatening viral diseases such as HIV or Chronic Hepatitis B. ABIVAX not only focuses on discovery and development, but also on commercialization.
TWO PRODUCTS IN ADVANCED CLINICAL TRIALS
ABIVAX has two compounds in clinical stage research: ABX464, a novel small molecule against HIV that could be a potential functional cure for HIV, and ABX203, a therapeutic vaccine with a long lasting effect against chronic hepatitis B.
TREAT SOME OF
THE WORLD'S MOST
ABIVAX is a pioneering biotech company. We have pioneered a unique and proprietary anti-viral platform technology, focused on the “killing” of RNA. This has already generated lead compounds for multiple viral diseases, such as Dengue and Chikungunya.
We are also pioneering partnerships, in particular with Cuba’s excellent life sciences companies.This partnerships have already provided us with an access to world-class vaccines, including commercial products against Typhoid, Meningitis B and C, and Leptospirosis.